Journal
TRANSFUSION MEDICINE REVIEWS
Volume 30, Issue 3, Pages 139-145Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.tmrv.2016.03.001
Keywords
T cells; Adoptive immunotherapy; Gene transfer; Leukapheresis; Cell processing
Categories
Funding
- National Cancer Institute [K08 CA166039]
- National Institutes of Health [5T32HL007775]
Ask authors/readers for more resources
The use of chimeric antigen receptor (CAR)-T cell therapy for the treatment of hematologic malignancies has generated significant excitement over the last several years. From a transfusion medicine perspective, the implementation of CAR-T therapy as a potential mainstay treatment for not only hematologic but also solid-organ malignancies represents a significant opportunity for growth and expansion. In this review, we will describe the rationale for the development of genetically redirected T cells as a cancer therapeutic, the different elements that are required to engineer these cells, as well as an overview of the process by which patient cells are harvested and processed to create and subsequently validate CAR-T cells. Finally, we will briefly describe some of the toxicities and clinical efficacy of CAR-T cells in the setting of patients with advanced malignancy. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available